These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
100 related articles for article (PubMed ID: 17931098)
1. Herbert Andre Fleisch, MD. Martin TJ; Bonjour JP; Russell RG J Bone Miner Res; 2007 Nov; 22(11):1651-3. PubMed ID: 17931098 [No Abstract] [Full Text] [Related]
2. Herbert Andre Fleisch, MD : 22 July 1933-15 May 2007. Martin TJ; Christiansen C; Kanis JA; Russell G Osteoporos Int; 2007 Aug; 18(8):1019-21. PubMed ID: 17598066 [No Abstract] [Full Text] [Related]
3. Historical perspectives on the clinical development of bisphosphonates in the treatment of bone diseases. Francis MD; Valent DJ J Musculoskelet Neuronal Interact; 2007; 7(1):2-8. PubMed ID: 17396000 [TBL] [Abstract][Full Text] [Related]
4. [Pamidronate and olpadronate discoverer, Prof. Olav Maria Leonard Bijvoet passed away]. Roldán EJ Medicina (B Aires); 2014; 74(5):425-7. PubMed ID: 25347910 [No Abstract] [Full Text] [Related]
5. A tribute to Herbert Fleisch. Rizzoli R; Osteoporos Int; 2007 Sep; 18(9):1151. PubMed ID: 17609841 [No Abstract] [Full Text] [Related]
6. Bisphosphonate-related osteonecrosis of the jaw (BRONJ): initial discovery and subsequent development. Ruggiero SL J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):13-8. PubMed ID: 19371810 [TBL] [Abstract][Full Text] [Related]
10. [Bisphosphonate treatment of osteoporosis and other skeletal diseases]. Syversen U; Halse JI Tidsskr Nor Laegeforen; 2011 Feb; 131(3):244-7. PubMed ID: 21304573 [TBL] [Abstract][Full Text] [Related]
11. [The return of phossy jaw?]. Broome M; Jaques B; Madrid C Rev Stomatol Chir Maxillofac; 2008 Jun; 109(3):203-5. PubMed ID: 18533213 [No Abstract] [Full Text] [Related]
12. [The use of bisphosphonates for treating pathological states in orthopedics]. Białecki P; Bohatyrewicz A; Machoy-Mokrzyńska A; Białecka M Chir Narzadow Ruchu Ortop Pol; 2008; 73(4):266-73. PubMed ID: 18847019 [TBL] [Abstract][Full Text] [Related]
14. Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid. Spence MM; Hui RL; Chan J; Schottinger JE Ann Pharmacother; 2010 Sep; 44(9):1384-8. PubMed ID: 20682850 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of bisphosphonates on bone pain and quality of life in breast cancer patients with metastatic bone disease: a review. Diel IJ Support Care Cancer; 2007 Nov; 15(11):1243. PubMed ID: 17393190 [TBL] [Abstract][Full Text] [Related]
16. [The efficacy and safety of bisphosphonate for patients with kidney disease]. Hiramatsu R; Ubara Y Clin Calcium; 2016 Sep; 26(9):1319-24. PubMed ID: 27561347 [TBL] [Abstract][Full Text] [Related]
17. [Focus: Drug-related osteonecrosis of the jaw]. Schmouchkovitch A; Remaud M; Simon H; Herry H; Le Toux G; Boisramé S Presse Med; 2018 Jan; 47(1):19-33. PubMed ID: 29275972 [TBL] [Abstract][Full Text] [Related]
18. Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Drake MT; Cremers SC Mol Interv; 2010 Jun; 10(3):141-52. PubMed ID: 20539033 [TBL] [Abstract][Full Text] [Related]
19. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid. Lein M; Miller K; Wirth M; Weissbach L; May C; Schmidt K; Haus U; Schrader M; Jung K Prostate; 2009 May; 69(6):624-32. PubMed ID: 19143027 [TBL] [Abstract][Full Text] [Related]
20. [The work of Andre Leri]. Liévre JA Sem Hop; 1971 May; 47(25):1630-7. PubMed ID: 4327906 [No Abstract] [Full Text] [Related] [Next] [New Search]